Cargando…
Comparison of Recommendations Made by Committee Members with and without Financial Conflict of Interest on Japanese Guideline of Treatment of Hyperuricemia and Gout, Third Edition
Clinical practice guidelines (CPGs) consist of clinical questions (CQs) and corresponding recommendations. Considering the estimation of body of evidence, patients’ opinions, and medical economics, recommendations can vary depending on the votes of the committee members of CPGs. Taking this into con...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628237/ https://www.ncbi.nlm.nih.gov/pubmed/37941684 http://dx.doi.org/10.31662/jmaj.2023-0067 |
_version_ | 1785131713088716800 |
---|---|
author | Hisatome, Ichiro Hamada, Toshihiro Mizuta, Einosuke Ohtahara, Akira Kuwabara, Masanari Ogino, Kazuhide Ninomiya, Haruaki Sato, Yasuto Nakayama, Takeo Yamanaka, Hisashi |
author_facet | Hisatome, Ichiro Hamada, Toshihiro Mizuta, Einosuke Ohtahara, Akira Kuwabara, Masanari Ogino, Kazuhide Ninomiya, Haruaki Sato, Yasuto Nakayama, Takeo Yamanaka, Hisashi |
author_sort | Hisatome, Ichiro |
collection | PubMed |
description | Clinical practice guidelines (CPGs) consist of clinical questions (CQs) and corresponding recommendations. Considering the estimation of body of evidence, patients’ opinions, and medical economics, recommendations can vary depending on the votes of the committee members of CPGs. Taking this into consideration, concerns have already been raised on how financial conflict of interest (COI) potentially influences recommendations. In this study, we developed the third edition of guideline for the management of hyperuricemia and gout. This CPG was composed of seven CQs and recommendations. The direction and strength of the recommendations were determined by votes. There are three CQs. Individual questions asked whether uric acid-lowering-agents (ULAs) could be applied to hyperuricemic patients with chronic kidney disease (CKD) (CQ A), hypertension (CQ B), or heart failure (CQ C) to prevent organ damage. We examined whether the absence (18 members) or presence (8 members) of COIs of committee members could influence the votes. In total, 26 committee members with and without COI have equally determined the direction and strength of recommendations. In CQ A, members without financial COIs and those with financial COI selected conditional recommendation for the use of ULAs in patients with CKD (without COI, 17/18; with COI, 7/8). In CQ B, members without financial COIs and those with financial COI selected conditional recommendation against the use of ULAs in hypertensive patients (without COI, 14/18; with COI, 5/8). In CQ C, members without financial COIs and those with financial COIs have selected conditional recommendation against the use of ULAs in patients suffering from heart failure (without COI, 15/18; with COI, 4/8). We found that members with financial COIs have determined their recommendations in the same direction and strength as those without financial COIs. |
format | Online Article Text |
id | pubmed-10628237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Japan Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-106282372023-11-08 Comparison of Recommendations Made by Committee Members with and without Financial Conflict of Interest on Japanese Guideline of Treatment of Hyperuricemia and Gout, Third Edition Hisatome, Ichiro Hamada, Toshihiro Mizuta, Einosuke Ohtahara, Akira Kuwabara, Masanari Ogino, Kazuhide Ninomiya, Haruaki Sato, Yasuto Nakayama, Takeo Yamanaka, Hisashi JMA J Opinion Clinical practice guidelines (CPGs) consist of clinical questions (CQs) and corresponding recommendations. Considering the estimation of body of evidence, patients’ opinions, and medical economics, recommendations can vary depending on the votes of the committee members of CPGs. Taking this into consideration, concerns have already been raised on how financial conflict of interest (COI) potentially influences recommendations. In this study, we developed the third edition of guideline for the management of hyperuricemia and gout. This CPG was composed of seven CQs and recommendations. The direction and strength of the recommendations were determined by votes. There are three CQs. Individual questions asked whether uric acid-lowering-agents (ULAs) could be applied to hyperuricemic patients with chronic kidney disease (CKD) (CQ A), hypertension (CQ B), or heart failure (CQ C) to prevent organ damage. We examined whether the absence (18 members) or presence (8 members) of COIs of committee members could influence the votes. In total, 26 committee members with and without COI have equally determined the direction and strength of recommendations. In CQ A, members without financial COIs and those with financial COI selected conditional recommendation for the use of ULAs in patients with CKD (without COI, 17/18; with COI, 7/8). In CQ B, members without financial COIs and those with financial COI selected conditional recommendation against the use of ULAs in hypertensive patients (without COI, 14/18; with COI, 5/8). In CQ C, members without financial COIs and those with financial COIs have selected conditional recommendation against the use of ULAs in patients suffering from heart failure (without COI, 15/18; with COI, 4/8). We found that members with financial COIs have determined their recommendations in the same direction and strength as those without financial COIs. Japan Medical Association 2023-09-25 2023-10-16 /pmc/articles/PMC10628237/ /pubmed/37941684 http://dx.doi.org/10.31662/jmaj.2023-0067 Text en Copyright © Japan Medical Association https://creativecommons.org/licenses/by/4.0/JMA Journal is an Open Access journal distributed under the Creative Commons Attribution 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Opinion Hisatome, Ichiro Hamada, Toshihiro Mizuta, Einosuke Ohtahara, Akira Kuwabara, Masanari Ogino, Kazuhide Ninomiya, Haruaki Sato, Yasuto Nakayama, Takeo Yamanaka, Hisashi Comparison of Recommendations Made by Committee Members with and without Financial Conflict of Interest on Japanese Guideline of Treatment of Hyperuricemia and Gout, Third Edition |
title | Comparison of Recommendations Made by Committee Members with and without Financial Conflict of Interest on Japanese Guideline of Treatment of Hyperuricemia and Gout, Third Edition |
title_full | Comparison of Recommendations Made by Committee Members with and without Financial Conflict of Interest on Japanese Guideline of Treatment of Hyperuricemia and Gout, Third Edition |
title_fullStr | Comparison of Recommendations Made by Committee Members with and without Financial Conflict of Interest on Japanese Guideline of Treatment of Hyperuricemia and Gout, Third Edition |
title_full_unstemmed | Comparison of Recommendations Made by Committee Members with and without Financial Conflict of Interest on Japanese Guideline of Treatment of Hyperuricemia and Gout, Third Edition |
title_short | Comparison of Recommendations Made by Committee Members with and without Financial Conflict of Interest on Japanese Guideline of Treatment of Hyperuricemia and Gout, Third Edition |
title_sort | comparison of recommendations made by committee members with and without financial conflict of interest on japanese guideline of treatment of hyperuricemia and gout, third edition |
topic | Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628237/ https://www.ncbi.nlm.nih.gov/pubmed/37941684 http://dx.doi.org/10.31662/jmaj.2023-0067 |
work_keys_str_mv | AT hisatomeichiro comparisonofrecommendationsmadebycommitteememberswithandwithoutfinancialconflictofinterestonjapaneseguidelineoftreatmentofhyperuricemiaandgoutthirdedition AT hamadatoshihiro comparisonofrecommendationsmadebycommitteememberswithandwithoutfinancialconflictofinterestonjapaneseguidelineoftreatmentofhyperuricemiaandgoutthirdedition AT mizutaeinosuke comparisonofrecommendationsmadebycommitteememberswithandwithoutfinancialconflictofinterestonjapaneseguidelineoftreatmentofhyperuricemiaandgoutthirdedition AT ohtaharaakira comparisonofrecommendationsmadebycommitteememberswithandwithoutfinancialconflictofinterestonjapaneseguidelineoftreatmentofhyperuricemiaandgoutthirdedition AT kuwabaramasanari comparisonofrecommendationsmadebycommitteememberswithandwithoutfinancialconflictofinterestonjapaneseguidelineoftreatmentofhyperuricemiaandgoutthirdedition AT oginokazuhide comparisonofrecommendationsmadebycommitteememberswithandwithoutfinancialconflictofinterestonjapaneseguidelineoftreatmentofhyperuricemiaandgoutthirdedition AT ninomiyaharuaki comparisonofrecommendationsmadebycommitteememberswithandwithoutfinancialconflictofinterestonjapaneseguidelineoftreatmentofhyperuricemiaandgoutthirdedition AT satoyasuto comparisonofrecommendationsmadebycommitteememberswithandwithoutfinancialconflictofinterestonjapaneseguidelineoftreatmentofhyperuricemiaandgoutthirdedition AT nakayamatakeo comparisonofrecommendationsmadebycommitteememberswithandwithoutfinancialconflictofinterestonjapaneseguidelineoftreatmentofhyperuricemiaandgoutthirdedition AT yamanakahisashi comparisonofrecommendationsmadebycommitteememberswithandwithoutfinancialconflictofinterestonjapaneseguidelineoftreatmentofhyperuricemiaandgoutthirdedition |